XGN Exagen Inc
Price (delayed)
$4.43
Market cap
$79.29M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.83
Enterprise value
$80.26M
Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and
Highlights
The EPS has grown by 38% YoY and by 12% from the previous quarter
The company's net income rose by 36% YoY and by 11% QoQ
Exagen's equity has plunged by 58% YoY and by 26% from the previous quarter
XGN's quick ratio is down by 39% year-on-year and by 38% since the previous quarter
Key stats
What are the main financial stats of XGN
Market
Valuations
Earnings
Shares outstanding
17.9M
Market cap
$79.29M
Enterprise value
$80.26M
Price to earnings (P/E)
N/A
Price to book (P/B)
8.19
Price to sales (P/S)
1.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.44
Revenue
$55.64M
Gross profit
$33.11M
Operating income
-$13.64M
Net income
-$15.12M
EBIT
-$12.87M
EBITDA
-$10.26M
Free cash flow
-$13.79M
Per share
Balance sheet
Liquidity
EPS
-$0.83
EPS diluted
-$0.83
Free cash flow per share
-$0.76
Book value per share
$0.54
Revenue per share
$3.06
TBVPS
$2.46
Total assets
$44.69M
Total liabilities
$35.15M
Debt
$23.01M
Equity
$9.54M
Working capital
$22.95M
Debt to equity
2.41
Current ratio
2.7
Quick ratio
2.21
Net debt/EBITDA
-0.09
Margins
Efficiency
Dividend
EBITDA margin
-18.4%
Gross margin
59.5%
Net margin
-27.2%
Operating margin
-24.5%
Return on assets
-32.1%
Return on equity
-100.8%
Return on invested capital
-35.5%
Return on capital employed
-41.3%
Return on sales
-23.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
XGN stock price
How has the Exagen stock price performed over time
Intraday
12.72%
1 week
4.24%
1 month
28.03%
1 year
193.38%
YTD
8.05%
QTD
23.4%
Financial performance
How have Exagen's revenue and profit performed over time
Revenue
$55.64M
Gross profit
$33.11M
Operating income
-$13.64M
Net income
-$15.12M
Gross margin
59.5%
Net margin
-27.2%
The operating margin has grown by 44% YoY and by 11% from the previous quarter
XGN's net margin is up by 40% year-on-year and by 11% since the previous quarter
The operating income rose by 40% year-on-year and by 11% since the previous quarter
The company's net income rose by 36% YoY and by 11% QoQ
Growth
What is Exagen's growth rate over time
Valuation
What is Exagen stock price valuation
P/E
N/A
P/B
8.19
P/S
1.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.44
The EPS has grown by 38% YoY and by 12% from the previous quarter
XGN's price to book (P/B) is 96% higher than its last 4 quarters average of 3.7
Exagen's equity has plunged by 58% YoY and by 26% from the previous quarter
The P/S is 44% less than the 5-year quarterly average of 2.3 but 43% more than the last 4 quarters average of 0.9
Exagen's revenue has increased by 6% YoY
Efficiency
How efficient is Exagen business performance
The ROS has grown by 43% YoY and by 12% from the previous quarter
The company's return on equity fell by 26% YoY and by 9% QoQ
The company's return on invested capital rose by 25% YoY and by 13% QoQ
Exagen's return on assets has increased by 12% YoY and by 4.7% QoQ
Dividends
What is XGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for XGN.
Financial health
How did Exagen financials performed over time
The total assets is 27% greater than the total liabilities
XGN's quick ratio is down by 39% year-on-year and by 38% since the previous quarter
Exagen's current ratio has decreased by 33% from the previous quarter and by 33% YoY
XGN's debt is 141% greater than its equity
The debt to equity has soared by 136% YoY and by 33% from the previous quarter
Exagen's equity has plunged by 58% YoY and by 26% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.